MEDLAB Clinical says preliminary results of its NanoStat (Nanocelle Atorvastatin) bioquivalence trial have shown significant improvement in drug delivery when compared to oral 20mg tablets of atorvastatin.
The company said NanoStat achieved faster peak concentrations and at least twice the blood levels of free atorvastatin, because it "cleaves" the calcium salt from the atorvastatin molecules prior to absorption by the body.
Medlab said it was its intention to investigate "the potential for a lower dose statin delivered as an oro-buccal spray, being similar to the effects of a stronger dose tablet".
The above article was sent to subscribers in Pharmacy Daily's issue from 10 Jan 19
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 10 Jan 19